Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.

被引：2
|
作者：
Liu, M. C. [1 ]
Dixon, J. M. [1 ]
Xuan, J. J. [1 ]
Riggins, R. B. [1 ]
Chen, L. [1 ]
Wang, C. [1 ]
Cho, Y. [1 ]
Zhu, Y. [1 ]
Jin, L. [1 ]
Zwart, A. [1 ]
Wang, M. [1 ]
Klimach, U. M. [1 ]
Wang, Y. J. [1 ]
Renshaw, L. [1 ]
Larionov, A. [1 ]
Miller, W. R. [1 ]
Clarke, R. [1 ]
机构：
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-S1-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-8
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen.
    Loi, SM
    Desmedt, C
    Haibe-Kains, B
    Lallemand, F
    Gillett, C
    Tutt, A
    Ryder, K
    Ellis, P
    Harris, P
    Smeds, J
    Bergh, J
    Cardoso, F
    Piccart, MJ
    Sotiriou, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S129 - S130
  • [2] Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen.
    McArthur, HK
    Olivotto, I
    Gelmon, KA
    Speers, CH
    Chia, S
    Ellard, S
    Kennecke, HF
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S124 - S124
  • [3] Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone
    Ingle, James N.
    Suman, Vera J.
    Solanki, Malvika H.
    Passow, Marie R.
    Campbell, Jordan D.
    Wang, Liewei
    Goetz, Matthew P.
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [4] Tipifarnib with tamoxifen as a rescue for tamoxifen acquired clinical resistance for metastatic ER and/or PgR positive breast cancer after releapse under tamoxifen.: Preliminary results
    Dalenc, F
    Lacroix-Tikri, M
    Mourey, L
    Debled, M
    Gladieff, L
    Tilkin, AF
    Faye, JC
    Seronie-Vivien, S
    Roché, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S241 - S241
  • [5] ADJUVANT TAMOXIFEN FOR EARLY BREAST-CANCER
    SMITH, I
    BRITISH JOURNAL OF CANCER, 1988, 57 (06) : 527 - 528
  • [6] ADJUVANT TAMOXIFEN IN EARLY BREAST-CANCER
    不详
    LANCET, 1987, 2 (8552): : 191 - 192
  • [7] Meta-analysis: Adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer
    Kiely, Belinda
    Stockler, Martin
    ANNALS OF INTERNAL MEDICINE, 2012, 156 (06)
  • [8] FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
    Turczyk, Lukasz
    Kitowska, Kamila
    Mieszkowska, Magdalena
    Mieczkowski, Kamil
    Czaplinska, Dominika
    Piasecka, Dominika
    Kordek, Radzislaw
    Skladanowski, Andrzej C.
    Potemski, Piotr
    Romanska, Hanna M.
    Sadej, Rafal
    NEOPLASIA, 2017, 19 (10): : 791 - 804
  • [9] Cost-effectiveness projections of anastrozole vs. tamoxifen as initial adjuvant therapy in ER-positive early breast cancer.
    Hillner, BE
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S156 - S156
  • [10] Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.
    Garber, JE
    Halabi, S
    Kaplan, E
    Edge, S
    Dressler, L
    Paskett, E
    Berliner, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 6S - 6S
12345